Immunogenicity risk assessment for biotherapeutics through in vitro detection of CD134 and CD137 on T helper cells
Biotherapeutics, which are biologic medications that are natural or bioengineered products of living cells, have revolutionized the treatment of many diseases. However, unwanted immune responses still present a major challenge to their widespread adoption. Many patients treated with biotherapeutics...
Saved in:
Main Authors: | Sivan Cohen (Author), Srividya Myneni (Author), Anna Batt (Author), Joyce Guerrero (Author), Jochen Brumm (Author), Shan Chung (Author) |
---|---|
Format: | Book |
Published: |
Taylor & Francis Group,
2021-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
An integrated approach for characterizing immunogenic responses toward a bispecific antibody
by: Sivan Cohen, et al.
Published: (2021) -
Validation of a Dendritic Cell and CD4+ T Cell Restimulation Assay Contributing to the Immunogenicity Risk Evaluation of Biotherapeutics
by: Michel Siegel, et al.
Published: (2022) -
Immunotherapy of melanoma with the immune costimulatory monoclonal antibodies targeting CD137
by: Li SY, et al.
Published: (2013) -
CD4+ T Helper Cell Plasticity in Infection, Inflammation, and Autoimmunity
by: Samuel Huber, et al.
Published: (2017) -
Hypothesis of a CD137/Eomes activating axis for effector T cells in HPV oropharyngeal cancers
by: Robin Baudouin, et al.
Published: (2024)